pyy glp 1 Schematic overview depicting regulatory pathways for and GLP-1 Ghrelin, CCK, GLP-1, and PYY(3-36):

As a compounded preparation, it has not undergone FDA review for safety, effectiveness, or manufacturing quality as a finished product, and it should not be treated as equivalent to Ozempic or Wegovy - those are the FDA-approved, brand-name semaglutide products, manufactured and reviewed separately by Novo Nordisk

T., Feldpausch, M

Mekaroonkamol, P

The LEADER trial with liraglutide reported a reduction in MACE (HR 0.87), while the REWIND trial with dulaglutide demonstrated an HR of 0.88

Buyer access

A statistically significant increase in thyroid C-cell adenomas and a numerical increase in C-cell carcinomas were observed in males and females at clinically relevant exposures